Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro

  • Authors:
    • A. Schindler
    • U. Fiedler
    • A. Meye
    • U. Schmidt
    • S. Fussel
    • C. Pilarsky
    • J. Herrmann
    • M. P. Wirth
  • View Affiliations

  • Published online on: July 1, 2001     https://doi.org/10.3892/ijo.19.1.25
  • Pages: 25-30
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Telomerase, a ribonucleoprotein complex is activated in the vast majority of human malignancies, including prostate cancer. Its inhibition is a putative way to affect cancer proliferation and might be used in the therapy of tumors. We analysed the influence of antisense phosphorothioate oligonucleotides (PTO) against the reverse transcriptase subunit of telomerase on prostate cancer cell viability, telomerase activity and telomere length. DU145 prostate cancer cells were cultivated in PTO containing medium. The PTO-incorporation was confirmed by confocal laser scanning microscopy. Cell viability was measured by a WST-1 tetrazolium assay. After 15 days of antisense PTO treatment, a significant inhibition of cell viability occurred. Telomerase activity was determined by a telomeric repeat amplification protocol (TRAP) assay and telomere length by Southern blot analysis. Since the long-term telomerase antisense treatment reduces the viability of prostate cancer cells significantly, this antisense approach could be a new therapeutic strategy to treat patients with advanced prostate cancer.

Related Articles

Journal Cover

July 2001
Volume 19 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Schindler A, Fiedler U, Meye A, Schmidt U, Fussel S, Pilarsky C, Herrmann J and Wirth MP: Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. Int J Oncol 19: 25-30, 2001.
APA
Schindler, A., Fiedler, U., Meye, A., Schmidt, U., Fussel, S., Pilarsky, C. ... Wirth, M.P. (2001). Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro. International Journal of Oncology, 19, 25-30. https://doi.org/10.3892/ijo.19.1.25
MLA
Schindler, A., Fiedler, U., Meye, A., Schmidt, U., Fussel, S., Pilarsky, C., Herrmann, J., Wirth, M. P."Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro". International Journal of Oncology 19.1 (2001): 25-30.
Chicago
Schindler, A., Fiedler, U., Meye, A., Schmidt, U., Fussel, S., Pilarsky, C., Herrmann, J., Wirth, M. P."Human telomerase reverse transcriptase antisense treatment downregulates the viability of prostate cancer cells in vitro". International Journal of Oncology 19, no. 1 (2001): 25-30. https://doi.org/10.3892/ijo.19.1.25